Sirolimus Whole Blood Test Price & Booking at Chughtai Lab

Sirolimus (Whole Blood) at Chughtai Lab

Sirolimus, commercially known as Rapamycin, is a highly potent immunosuppressive agent widely utilized in modern transplant medicine and specialized oncology. The Sirolimus (Whole Blood) test at Chughtai Lab is a critical diagnostic tool designed to measure the precise concentration of this medication in a patient’s bloodstream. Because sirolimus possesses a narrow therapeutic index—meaning the margin between an effective therapeutic dose and a toxic dose is extremely small—precise monitoring of its blood levels is essential to ensure patient safety and therapeutic efficacy. This process is clinically referred to as Therapeutic Drug Monitoring (TDM).

Sirolimus functions by inhibiting the mechanistic target of rapamycin (mTOR), a key kinase enzyme that regulates cell growth, proliferation, and survival. By blocking this pathway, sirolimus suppresses T-lymphocyte activation and antibody production, which are the primary drivers of immune-mediated organ transplant rejection. In addition to its role in solid organ transplantation, particularly renal transplants, sirolimus is also indicated for the treatment of lymphangioleiomyomatosis (LAM), a rare and progressive lung disease characterized by abnormal smooth muscle-like cell growth. It is also used off-label in various other clinical scenarios, including cardiac stent coatings and specific oncological protocols.

At Chughtai Lab, Pakistan’s premier diagnostic network, the Sirolimus (Whole Blood) test is performed using advanced analytical methodologies, such as Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) or highly sensitive chemiluminescent microparticle immunoassays (CMIA). Because sirolimus extensively partitions into red blood cells (erythrocytes)—with approximately 95% of the drug bound to cellular components—the test must be performed on whole blood rather than serum or plasma. This ensures a true representation of the systemic drug concentration. Regular monitoring allows transplant physicians and specialists to customize dosages, prevent acute graft rejection, minimize drug-induced toxicities, and manage complex drug-drug interactions, ultimately improving long-term patient outcomes and graft survival.

Clinical Procedure: What to Expect

Patient Preparation

• Timing of Collection: The blood sample must be collected as a “trough” level. This means the draw must occur immediately before the next scheduled dose of sirolimus, typically within 15 to 30 minutes prior to administration.
• Consistency in Dosing: Ensure that the medication has been taken at the same time every day for at least 5 to 7 days prior to the test, as sirolimus has a long half-life (approximately 60 hours) and requires time to reach steady-state concentration.
• Dietary Restrictions: While fasting is generally not mandatory, patients should maintain a consistent diet. Avoid consuming grapefruit, grapefruit juice, or Seville oranges, as these substances inhibit the CYP3A4 enzyme and can artificially elevate sirolimus levels.
• Medication History: Provide a complete list of all current medications, over-the-counter drugs, and herbal supplements to the laboratory staff. Drugs such as ketoconazole, erythromycin, rifampin, and diltiazem significantly alter sirolimus metabolism.
• Hydration: Drink plenty of water before the procedure to ensure easy venous access and a smooth blood collection process.

During the Procedure

The procedure is a standard venipuncture performed by an experienced phlebotomist at Chughtai Lab. The patient is seated comfortably, and an elastic band (tourniquet) is applied to the upper arm to make the veins more visible and accessible. The puncture site, usually the inner elbow (antecubital fossa), is thoroughly cleansed with an antiseptic solution to prevent contamination. A sterile needle is inserted into the vein, and the blood is collected directly into an EDTA (ethylenediaminetetraacetic acid) tube, characterized by its purple top. EDTA is the required anticoagulant because it preserves whole blood integrity, which is essential for accurate sirolimus measurement. Once the sample is collected, the needle is gently withdrawn, pressure is applied to the site with a sterile cotton swab, and a bandage is applied. The entire process takes less than five minutes and is associated with minimal discomfort, similar to a brief pinprick. The sample is then carefully labeled with the patient’s details, the exact time of the blood draw, and the time of the last drug dose, before being transported under controlled temperature conditions to the specialized testing department.

When is a Sirolimus (Whole Blood) Test Performed?

Prevention of Renal Transplant Rejection

Following a kidney transplant, the recipient’s immune system naturally recognizes the donor organ as foreign and attempts to destroy it. Sirolimus is prescribed as part of an immunosuppressive regimen to prevent this acute or chronic rejection. Physicians request the Sirolimus (Whole Blood) test regularly to ensure that the drug concentration remains within the therapeutic window. If levels drop too low, the risk of graft rejection increases significantly, which can lead to irreversible organ damage. Conversely, maintaining optimal levels helps preserve the structural and functional integrity of the transplanted kidney.

Management of Lymphangioleiomyomatosis (LAM)

Lymphangioleiomyomatosis is a rare cystic lung disease that primarily affects women of childbearing age. In LAM, abnormal smooth muscle cells grow uncontrollably in the lungs, kidneys, and lymphatic system, leading to progressive respiratory impairment. Because these cells exhibit hyperactive mTOR signaling, sirolimus is used to slow down disease progression and stabilize lung function. Regular blood tests are requested by pulmonologists to monitor sirolimus levels, ensuring the dose is sufficient to inhibit cell proliferation while avoiding systemic side effects like pneumonitis or severe hyperlipidemia.

Monitoring Post-Dosage Adjustments

Whenever a patient’s sirolimus dosage is modified, or when transitioning from other immunosuppressants (such as tacrolimus or cyclosporine) to sirolimus, close monitoring is required. Because sirolimus has an exceptionally long half-life of approximately 50 to 60 hours, it takes several days for the blood concentration to stabilize at a new steady state. Physicians request the test approximately 5 to 7 days after any dose adjustment to evaluate the impact of the change and ensure the patient safely transitions into the new therapeutic range.

Evaluation of Potential Drug Toxicity

Sirolimus therapy is associated with several dose-dependent toxicities, including myelosuppression (resulting in anemia, leukopenia, and thrombocytopenia), hypercholesterolemia, hypertriglyceridemia, impaired wound healing, and interstitial pneumonitis. If a patient presents with symptoms such as unexplained fatigue, bruising, shortness of breath, or abnormal lipid profiles, the physician will order a Sirolimus (Whole Blood) test. This helps determine if the symptoms are linked to supratherapeutic drug levels, allowing the clinician to safely reduce the dose or temporarily hold therapy.

Assessment of Drug-Drug Interactions and Compliance

Sirolimus is a substrate for both the cytochrome P450 3A4 (CYP3A4) enzyme system and the P-glycoprotein (P-gp) efflux pump. Consequently, co-administration with common medications—such as azole antifungals, macrolide antibiotics, calcium channel blockers, or anticonvulsants—can dramatically alter its blood concentration. Clinicians request this test whenever a new interacting drug is introduced or discontinued. Additionally, the test is invaluable for assessing patient compliance, as fluctuating or unexpectedly low levels may indicate irregular medication adherence, which poses a severe threat to graft survival.

What Does a Sirolimus (Whole Blood) Test Detect?

The Sirolimus (Whole Blood) test detects and evaluates several critical clinical parameters and physiological states, including:

• Therapeutic Trough Levels: Confirms whether the drug concentration is within the target therapeutic range (typically 4 to 20 ng/mL, depending on the clinical protocol).
• Subtherapeutic Concentrations: Detects drug levels below the therapeutic threshold, indicating an elevated risk of acute or chronic organ transplant rejection.
• Supratherapeutic Concentrations: Identifies excessively high drug levels, which significantly increase the risk of systemic toxicity and adverse drug reactions.
• Steady-State Achievement: Evaluates whether the drug has reached a stable concentration in the bloodstream after continuous dosing.
• Patient Compliance Issues: Detects unexpectedly low or undetectable levels, suggesting non-adherence to the prescribed medication schedule.
• CYP3A4 Inhibition Effects: Detects elevated sirolimus levels caused by concurrent use of CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin).
• CYP3A4 Induction Effects: Detects reduced sirolimus levels resulting from concurrent use of CYP3A4 inducers (e.g., rifampin, carbamazepine).
• Risk of Myelosuppression: Correlates high drug levels with potential bone marrow suppression, leading to leukopenia, thrombocytopenia, or anemia.
• Hyperlipidemia Risk Factors: Identifies supratherapeutic levels that may contribute to severe elevations in serum cholesterol and triglycerides.
• Impaired Wound Healing Potential: Highlights high drug concentrations that can interfere with tissue repair and surgical wound healing post-transplantation.
• mTOR Pathway Inhibition Efficacy: Indirectly reflects the degree of systemic mTOR pathway suppression required to manage diseases like LAM.
• Inter-individual Pharmacokinetic Variation: Identifies unique patient metabolic rates, helping customize personalized dosing regimens.
• Hepatic Clearance Capacity: Detects elevated levels in patients with hepatic impairment, as sirolimus is heavily metabolized by the liver.
• Absorption Abnormalities: Identifies poor gastrointestinal absorption or bioavailability issues affecting drug levels.
• Drug-Induced Nephrotoxicity Risk: Evaluates the potential for renal damage, particularly when sirolimus is used in combination with calcineurin inhibitors.
• Risk of Interstitial Lung Disease: Associates high blood concentrations with the development of drug-induced non-infectious pneumonitis.
• Gastrointestinal Side Effect Correlation: Helps link high drug levels to symptoms like aphthous ulcers (mouth sores), diarrhea, or abdominal pain.
• Risk of Microangiopathy: Identifies high-dose exposure that may contribute to transplant-associated thrombotic microangiopathy (TMA).
• Pediatric Clearance Variations: Detects rapid clearance rates typical in pediatric patients, who often require higher weight-based doses.
• Impact of Dietary Interactions: Identifies fluctuations in drug levels caused by dietary inconsistencies, such as consuming high-fat meals or interacting juices.
• Post-Transplant Lymphoproliferative Disorder (PTLD) Risk Mitigation: Helps maintain optimal immunosuppression to balance the risk of viral-associated malignancies.
• Graft-versus-Host Disease (GVHD) Prophylaxis Efficacy: Monitors levels when used off-label to prevent GVHD in hematopoietic stem cell transplant recipients.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is Pakistan’s leading diagnostic network, utilizing state-of-the-art laboratory medicine infrastructure. Due to the highly specialized nature of the Sirolimus (Whole Blood) test, which requires advanced analytical platforms like Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) or automated chemiluminescent microparticle immunoassays (CMIA), the turnaround time is typically 24 to 48 hours. Once the analysis is completed and verified by a Consultant Pathologist, patients receive an automated SMS notification. Reports can be accessed immediately online via the official Chughtai Lab website (www.chughtailab.com) or through the user-friendly Chughtai Lab Mobile App. Patients can also collect printed copies of their reports from any of the numerous Chughtai Lab collection centers located across Lahore, Karachi, Islamabad, Peshawar, Multan, and other major cities.

Sirolimus (Whole Blood) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Therapeutic Trough Level (with Cyclosporine)	4.0 – 12.0 ng/mL (target varies by protocol)	< 4.0 ng/mL (Subtherapeutic, risk of rejection); > 12.0 ng/mL (Supratherapeutic, toxicity risk)
Therapeutic Trough Level (without Cyclosporine)	12.0 – 20.0 ng/mL (target varies by protocol)	< 12.0 ng/mL (Increased risk of rejection); > 20.0 ng/mL (Severe toxicity risk)
Lymphangioleiomyomatosis (LAM) Target	5.0 – 15.0 ng/mL (or as clinically indicated)	Outside target range (Inefficacy or adverse effects)
Red Blood Cell Partitioning	Normal hematocrit-dependent distribution	Altered distribution in severe anemia or polycythemia
Steady-State Achievement	Reached within 5 to 7 days of stable dosing	Fluctuating levels due to premature sampling or non-compliance
CYP3A4 Inhibitor Co-administration	No significant interaction	Markedly elevated sirolimus levels (toxicity risk)
CYP3A4 Inducer Co-administration	No significant interaction	Markedly reduced sirolimus levels (rejection risk)
Renal Function (with Calcineurin Inhibitors)	Stable serum creatinine	Elevated creatinine (potentiated nephrotoxicity)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Sirolimus (Whole Blood)?

• Experienced healthcare professionals and consultant pathologists overseeing specialized therapeutic drug monitoring.
• Patient-focused care ensuring a comfortable and professional environment during sample collection.
• Quality diagnostic services utilizing state-of-the-art analytical equipment and automated systems.
• Professional reporting with high clinical accuracy and meticulous quality control protocols.
• Modern diagnostic approach with seamless integration of digital health solutions.
• Comfortable environment at all collection centers with highly trained phlebotomists.
• Convenient locations across Pakistan, making specialized testing accessible to everyone.
• Commitment to accurate diagnosis, providing reliable results essential for critical post-transplant management.